Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder

Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder ("AUD"), today announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD).

Part B marks Clearmind’s first clinical evaluation of CMND‑100 in patients diagnosed with AUD, following the successful completion of Part A in healthy volunteers. Part B consists of two sequential single-dose ascending cohorts (80 mg and 160 mg), each consisting of six patients, designed to assess safety, tolerability, pharmacokinetics, and early signals of clinical efficacy, including potential reductions in alcohol craving.